| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 594 | 2017 |
| Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3–a prospective observational study MC Walter, S Wenninger, S Thiele, J Stauber, M Hiebeler, E Greckl, ... Journal of neuromuscular diseases 6 (4), 453-465, 2019 | 171 | 2019 |
| European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10‐year experience AT van der Ploeg, ME Kruijshaar, A Toscano, P Laforêt, C Angelini, ... European journal of neurology 24 (6), 768-e31, 2017 | 149 | 2017 |
| Toward deconstructing the phenotype of late‐onset Pompe disease A Schüller, S Wenninger, N Strigl‐Pill, B Schoser American Journal of Medical Genetics Part C: Seminars in Medical Genetics …, 2012 | 134 | 2012 |
| Core clinical phenotypes in myotonic dystrophies S Wenninger, F Montagnese, B Schoser Frontiers in neurology 9, 372687, 2018 | 131 | 2018 |
| Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial K Okkersen, C Jimenez-Moreno, S Wenninger, F Daidj, J Glennon, ... The Lancet Neurology 17 (8), 671-680, 2018 | 107 | 2018 |
| Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial J Diaz-Manera, PS Kishnani, H Kushlaf, S Ladha, T Mozaffar, V Straub, ... The Lancet Neurology 20 (12), 1012-1026, 2021 | 94 | 2021 |
| The impact of antibodies in late-onset Pompe disease: a case series and literature review TT Patel, SG Banugaria, LE Case, S Wenninger, B Schoser, PS Kishnani Molecular genetics and metabolism 106 (3), 301-309, 2012 | 89 | 2012 |
| Functional neuroanatomy of CCK‐4‐induced panic attacks in healthy volunteers D Eser, G Leicht, J Lutz, S Wenninger, V Kirsch, C Schüle, S Karch, ... Human brain mapping 30 (2), 511-522, 2009 | 89 | 2009 |
| Respiratory involvement in neuromuscular disorders M Boentert, S Wenninger, VA Sansone Current opinion in neurology 30 (5), 529-537, 2017 | 83 | 2017 |
| Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness Z Lukacs, P Nieves Cobos, S Wenninger, TA Willis, M Guglieri, M Roberts, ... Neurology 87 (3), 295-298, 2016 | 83 | 2016 |
| Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort SA Cumming, C Jimenez-Moreno, K Okkersen, S Wenninger, F Daidj, ... Neurology 93 (10), e995-e1009, 2019 | 77 | 2019 |
| Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double … B Schoser, M Roberts, BJ Byrne, S Sitaraman, H Jiang, P Laforêt, ... The Lancet Neurology 20 (12), 1027-1037, 2021 | 68 | 2021 |
| Utility of a next-generation sequencing-based gene panel investigation in German patients with genetically unclassified limb-girdle muscular dystrophy M Kuhn, D Gläser, PR Joshi, S Zierz, S Wenninger, B Schoser, ... Journal of neurology 263, 743-750, 2016 | 66 | 2016 |
| “Orbiting around” the orbital myositis: clinical features, differential diagnosis and therapy F Montagnese, S Wenninger, B Schoser Journal of neurology 263, 631-640, 2016 | 64 | 2016 |
| Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study A van der Ploeg, PG Carlier, RY Carlier, JT Kissel, B Schoser, ... Molecular genetics and metabolism 119 (1-2), 115-123, 2016 | 63 | 2016 |
| Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study … B van Engelen, OPTIMISTIC consortium Trials 16, 1-19, 2015 | 61 | 2015 |
| Sleep‐related symptoms and sleep‐disordered breathing in adult P ompe disease M Boentert, N Karabul, S Wenninger, B Stubbe‐Dräger, E Mengel, ... European journal of neurology 22 (2), 369-e27, 2015 | 57 | 2015 |
| Practical recommendations for diagnosis and management of respiratory muscle weakness in late-onset Pompe disease M Boentert, H Prigent, K Várdi, HN Jones, U Mellies, AK Simonds, ... International journal of molecular sciences 17 (10), 1735, 2016 | 54 | 2016 |
| Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2 F Montagnese, S Mondello, S Wenninger, W Kress, B Schoser Journal of Neurology 264, 2472-2480, 2017 | 52 | 2017 |
Olimpia Musumeciprofessor of Neurology , University of Messina在 unime.it 的电子邮件经过验证
